Nurix Therapeutics (NRIX) Q3 2026 Earnings
Includes $653.2 million of one-time license revenue recognized from the Roche collaboration and $34.4 million in one-time G&A expenses for Roche transaction consulting and business development costs
How Did NRIX Stock React to Q3 2026 Earnings?
S&P 500 over the same 30 days: −2.69%.
Did NRIX Beat Earnings? Q3 2026 Results
No. Nurix Therapeutics reported Q3 2026 earnings of $4.73 a share on Oct 13, 2026, missing the $5.11 consensus estimate by 7.5%. Revenue was $673.1M against a $479.5M estimate.
Nurix Therapeutics posted a revenue beat but an earnings miss in fiscal Q3 2026, as a transformational collaboration with Roche reshaped the company's financial profile almost overnight. Revenue surged to $673.06 million from just $7.89 million a year ago, a gain of 8,426.3% that cleared the $479.52 million consensus estimate by 40.36%, with $653.16 million of that total tied to one-time license revenue recognized from the Roche deal for bexobrutideg. GAAP earnings per diluted share came in at $4.73, which includes that $653.2 million in one-time license revenue as well as $34.4 million in one-time consulting and business development costs tied to the transaction; even so, the result fell 7.50% short of the $5.11 consensus. The company swung to net income of $549.81 million from a loss of $86.42 million in the prior-year period. With roughly $1.10 billion in cash now on hand, Nurix has guided runway into the second half of 2029, while the registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg against pirtobrutinib advances as the program's central near-term catalyst.
- $653.2 million license revenue from Roche collaboration drove revenue surge
- $10 million Sanofi milestone for first patient dosed in STAT6 degrader Phase 1 trial
- $7 million Pfizer milestone achievement
- $10 million one-time fee from Gilead for research term extension
- R&D expense reduction from Roche cost-sharing offset
“The third quarter marked an important transition for Nurix as we moved bexobrutideg into Phase 3 development in CLL and began executing a broader clinical strategy designed to realize its potential across lines of therapy in both oncology and auto-immune disease.”
Nurix Therapeutics CEO, on the earnings call
What Is Nurix Therapeutics's Outlook?
Nurix has approximately $1.1 billion in cash, cash equivalents and marketable securities providing runway into the second half of 2029. The company is executing a broad clinical development strategy for bexobrutideg spanning multiple hematologic malignancies, combination approaches in CLL, and expansion into immune-mediated diseases including chronic spontaneous urticaria (CSU) and multiple sclerosis (MS). Development costs for bexobrutideg are shared 40% by Nurix and 60% by Roche, with equal U.S. profit/loss sharing and tiered royalties on ex-U.S. sales. NX-1607 expansion cohorts across four solid tumor indications are each planned to enroll approximately 30 patients. Nurix remains eligible to receive approximately $455 million in future development, regulatory, and commercial milestones from Sanofi for the STAT6 program, plus potential royalties.
NRIX YoY Financials
| Metric | Q3 2026 | Q3 2025 | Year over year |
|---|---|---|---|
| Revenue | $673.1M | $7.9M | +8,426.3% |
| Operating Income | $559.5M | $68.9M | +712.2% |
| Net Income | $549.8M | $65.8M | +736.2% |
NRIX Revenue by Segment
When Does Nurix Therapeutics Report Next?
Figures from SEC filings and company reports. Not investment advice.